Good Morning Market Enthusiast,

This ticker should be no stranger if you’ve followed my alerts for any length of time.

At one point, it was one of the biggest winners I’ve ever flagged—running more than 300% from where I first called it out.

In 2025 alone, it has given us seven separate runs, including intraday moves of 24%, 17%, 13%, 11%, and 10%.

That’s not a theory. That’s a history of momentum in action. 🏃

Right now, the company is sitting at a level that deserves a close look. It has repeatedly bounced off its $1.45–$1.50 support zone throughout August.

As long as that floor holds, downside risk looks defined.

On the upside, clearing $1.75 and then $2.00 could set the stage for another retest of the $2.45 spike zone.

But the real story isn’t just the chart.

In the past few weeks,MAIA Biotechnology, Inc. (Nasdaq: MAIA) has delivered two powerful updates that change the complexion of the entire setup. (18)(19)

(19)
 

📰 Fresh Catalysts (11)(12)(17)(19)

Peer-Reviewed Publication (Aug 27)

On August 27, MAIA announced its Phase 2 THIO-101 clinical trial developments were published in Cells, an international peer-reviewed journal.

The article reinforced the company’s unique sequencing strategy: dosing Ateganosine (THIO) before checkpoint inhibitors to overcome resistance where conventional immunotherapies stall out.

CEO Vlad Vitoc noted: “Our novel combination strategy of ateganosine sequenced with a checkpoint inhibitor stands out, showing encouraging results in a population with high unmet medical need.”

Peer-reviewed validation like this isn’t window dressing. It is evidence that the oncology community is watching—and recognizing—the science.

IASLC World Conference on Lung Cancer (Sept 5)

Just days later, MAIA announced its abstract was selected for poster presentation at the prestigious IASLC World Conference on Lung Cancer in Barcelona.

Key points:

• Median overall survival (OS) of 17.8 months in heavily pre-treated NSCLC patients (vs. 5–6 months for standard chemotherapy).
   
• Progression-free survival (PFS) durability data to be presented live at the conference.
   
• Recent FDA Fast Track designation creates the possibility for Accelerated Approval and Priority Review, potentially bringing an FDA decision as soon as next year.
   

IASLC is one of the most respected oncology gatherings in the world. It’s not a marketing stage—it’s where the global lung cancer field gathers to decide what’s real and what’s noise. MAIA getting a slot there is validation that this story is climbing into the global spotlight.

(19)

🧬 The Core Science (10)(11)(16)(18)(19)

At the heart of it all is Ateganosine (THIO)—MAIA’s flagship product candidate and the only clinical-stage telomere-targeting anticancer agent.

How it works:

• Cancer cells depend on telomeres—the protective DNA caps at the ends of chromosomes—to replicate endlessly.
   
• THIO selectively breaks down those caps, triggering rapid cancer cell death.
   
• At the same time, it primes the immune system to keep fighting even after dosing stops.
   

This dual-action mechanism—direct cytotoxicity plus immune activation—sets THIO apart from existing treatments that target only one pathway.

Recent clinical evidence:

• THIO-101 Phase 2 trial (June 5 update): Median OS of 17.8 months with THIO + Regeneron’s Libtayo. That’s nearly triple the 5–6 months seen with chemo standard-of-care.
   
• Global expansion: In July, MAIA dosed the first patient in Taiwan, broadening enrollment and strengthening its dataset.
   
• Partnerships with pharma heavyweights: Roche and Regeneron are both engaged. Preclinical data suggest Ateganosine and Roche’s Tecentriq® are “highly synergistic,” while Regeneron’s checkpoint inhibitor Libtayo® is already in the THIO-101 study.
   

When billion-dollar companies like Roche and Regeneron put their names beside a micro-cap’s drug candidate, the market takes notice.

(19)

📊 The Math Gap (14)(15)(18)(19)

The science is compelling, but the math is just as striking.

• Cash position: ~$15.5M.
   
• Holdings: ~$22.5M in TNF preferred stock plus ~$7M in other public equities, including ~$5M in Femasys (FEMY).
   
• Total assets: ~$55M.
   
• Market cap: ~$6–7M.
   

That’s nearly a 10-to-1 disconnect between assets and valuation.

Diamond Equity Research recently reaffirmed its target of $10.27 per share—an over 550% premium to the current.

This isn’t an abstract calculation. It’s the kind of balance sheet mismatch that doesn’t stay unresolved for long, especially in a thin-float name.

💼 Insider Conviction (19)

Company insiders clearly see it. Since November, they’ve purchased more than 600,000 shares.

When the people closest to the science and the balance sheet are putting their own money down, it’s worth paying attention.

(19)

🧩 Why Now (11)(12)(14)(17)(18)(19)

• Peer-reviewed validation raises scientific credibility.
   
• Global oncology spotlight at IASLC ensures visibility with world-class researchers and clinicians.
   
• Fast Track designation accelerates the timeline.
   
• Balance sheet strength and analyst coverage point to multiples above current pricing.
   
• Momentum memory shows the ticker knows how to move when attention lands.
   

The floor is defined. The catalysts are stacking. The science is validated.

🎯 The Takeaway (11)(12)(17)(18)(19)

MAIA isn’t a new story. It’s a proven mover—one of my biggest winners ever, with seven more intraday surges already in 2025.

Now it’s back in focus, and the timing couldn’t be more interesting. 

With peer-reviewed publication, a global conference spotlight, and Fast Track designation all hitting in a matter of days, the narrative is building in real time.

Stay sharp and stay locked in. 

MAIA has stepped back into the spotlight—and history suggests it doesn’t wait around once the fire catches. 💥

To your success,

Max Masters

Co-founder, Market Tips Newsletter

Sources:
1. https://bit.ly/4cLWaog

2. https://bit.ly/4cRuZZk

3. https://bit.ly/42pGNOM

4. https://bit.ly/4cVjJLl

5. https://bit.ly/4jmedDM

6. https://bit.ly/3GjzjEx

7. https://bit.ly/4lIXYlV
8. https://bit.ly/4lKdluq
9. https://bit.ly/3GminNn

10. https://finance.yahoo.com/news/maia-biotechnology-announces-first-patient-131500434.html
11. https://finance.yahoo.com/news/maia-biotechnology-announces-peer-reviewed-131700117.html
12. https://finance.yahoo.com/news/maia-biotechnology-receives-fda-fast-120100331.html
13. https://finance.yahoo.com/news/maia-biotechnology-granted-european-patent-130100345.html

14. https://finance.yahoo.com/news/diamond-equity-research-releases-note-120000909.html

15. https://ml.globenewswire.com/Resource/Download/b5e1fff3-02a0-4a78-b533-2ec8845f612e

16. https://finance.yahoo.com/news/maia-biotechnology-announces-publication-interim-130100253.html
17. https://finance.yahoo.com/news/maia-biotechnology-abstract-selected-poster-130300068.html

18. https://maiabiotech.com/
19. https://ir.maiabiotech.com/company-information/presentations

Paid Promotion. Momentum Media LLC has been hired for a period beginning on 09/10/2025 and ending on 09/11/2025 (the “Campaign”) to publicly disseminate information about MAIA Biotechnology Inc. (MAIA:US). Momentum Media LLC has been compensated $7,500.00 and are owed an additional $0 for the Campaign. To date, we have been paid $69,600.00. Please read Momentum Media LLC’s complete disclaimer at https://markettips.net/disclaimer/ which includes important information. Emojis, graphics and/or images used herein have no specific or implied meaning, and are used for artistic purposes only. Nothing contained herein is financial advice. Momentum Media LLC is not an analyst, st.o.ck broker, financial adviser or st.o.ck picker nor is it qualified to act in the capacity of any of the foregoing. Information herein is a paid advertisement and should not be relied upon as accurate or complete.